Patent ID: 8686043

Claim:
A method for treating an AMPA receptor-mediated condition in a mammal selected from the group consisting of dementia, Alzheimer's disease, cognitive disorders, idiopathic and drug-induced Parkinson's disease, psychosis, schizophrenia, mood disorders, depression, attention deficit/hyperactivity disorder, and attention deficit disorder, comprising administering to the mammal a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein each R 1 and each R 2 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, â€”CF 3 , â€”CN, â€”(NR 8 )â€”(Câ•O)â€”R 8 , â€”(Câ•O)â€”OR 8 , â€”(Câ•O)â€”N(R 8 ) 2 , â€”OR 8 , â€”N(R 8 ) 2 , â€”SO 2 â€”N(R 8 ) 2 , and (C 1 -C 6 )alkyl; wherein said (C 1 -C 6 )alkyl is optionally substituted with one, two, three or four R 9 ; m is zero, or one; n is zero, one, two or three; p is zero; q is zero; s is one and t is one; or one of s or t is one and the other of s or t is two; R 3 is hydrogen; each R 4 is hydrogen; R 5 is hydrogen; R 6 is (C 1 -C 6 )alkyl-SO 2 ; R 8 is independently selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl and (C 3 -C 10 )cycloalkyl; wherein said (C 1 -C 6 )alkyl may be optionally substituted with one, two or three halo; each R 9 is independently selected from the group consisting of halogen and (NR 10 )â€”SO 2 â€”R 10 ; R 10 is independently selected from the group consisting of hydrogen and (C 1 -C 6 )alkyl; ring â€œAâ€ is (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, or (C 1 -C 9 )heterocycloalkyl; wherein two of said R 1 substituents on said (C 1 -C 9 )heterocycloalkyl may optionally be attached to the same carbon atom and may optionally be taken together to be oxo; ring â€œBâ€ is phenyl or pyridinyl; â€œXâ€ is â€”Oâ€” or >C(R 4 ) 2 ; â€œYâ€ is absent; and â€œZâ€ is â€”O.